Grant: Project Grant
Research Institute of the McGill University Health Centre
$810,900.00
Investigating the mechanisms underlying the Rac1/Cdc42 GTPase regulator CdGAP in breast cancer
EF 2021-22
Résumé
Lay Abstract:
Breast cancer is the second cause of cancer-related deaths amongst women after lung cancer. The availability of a wide range of therapeutic approaches creates a need for the development of individualized medicine leading to more accurate and efficient treatment responses. There is a special need to distinguish high-risk patients who require more aggressive chemotherapies combined to surgery versus low-risk patients who do not need invasive therapies like mastectomy. The proposed project has the very high potential to develop targeted novel therapeutic strategies for the treatment of breast cancer metastasis and therefore, will be of great interest for breast cancer patients and clinicians.
Programme
Project Grant
Emplacement
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
452222
Name
Lamarche-Vane Nathalie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cell Biology - Disease
Projecttitle
Investigating the mechanisms underlying the Rac1/Cdc42 GTPase regulator CdGAP in breast cancer
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$810,900
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Breast Cancer; Cell Signaling; Crispr/Cas9; Human Breast Cancer Cell Lines; Mouse Models; Rho Gtpases; Rhogaps; Tumor Angiogenesis; Vascular Development
Abstract
Lay Abstract:
Breast cancer is the second cause of cancer-related deaths amongst women after lung cancer. The availability of a wide range of therapeutic approaches creates a need for the development of individualized medicine leading to more accurate and efficient treatment responses. There is a special need to distinguish high-risk patients who require more aggressive chemotherapies combined to surgery versus low-risk patients who do not need invasive therapies like mastectomy. The proposed project has the very high potential to develop targeted novel therapeutic strategies for the treatment of breast cancer metastasis and therefore, will be of great interest for breast cancer patients and clinicians.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Lamarche-Vane, Nathalie
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $810,900~ $0~
